Adaani E. Frost, MD

Professor of Medicine, Institute for Academic Medicine
Houston Methodist
Weill Cornell Medical College


Publications

Early clearance vs persistence of de novo donor-specific antibodies following lung transplantation
Islam, AK, Sinha, N, DeVos, JM, Kaleekal, TS, Jyothula, SS, Teeter, LD, Nguyen, DTM, Eagar, TN, Moore, LW, Puppala, M, Wong, STC, Knight, RJ, Frost, AE, Graviss, EA & Osama Gaber, A 2017, Clinical Transplantation. DOI: 10.1111/ctr.13028

The Impact of Scleroderma Diagnosis on Lung Transplant Outcomes: A Single Center's Experience
Memon, HA, Frost, AE, Graviss, EA, Nguyen, DTM, Goodarzi, A & Sinha, N 2017, 2017 American Transplant Congress, 4/30/17, .

Longitudinal change in pulmonary arterial capacitance as an indicator of prognosis and response to therapy and in pulmonary arterial hypertension
Medrek, SK, Kloefkorn, C, Nguyen, DTM, Graviss, EA, Frost, AE & Safdar, Z 2017, Pulmonary Circulation, vol 7, no. 2, pp. 399-408. DOI: 10.1177/2045893217698715

Tolerability of Switch to Macitentan from Bosentan in Pulmonary Arterial Hypertension
Safdar, Z, Thakur, A & Frost, A 2017, Southern Medical Journal, vol 110, no. 3, pp. 223-228. DOI: 10.14423/SMJ.0000000000000607

Longitudinal change in pulmonary arterial capacitance as an indicator of prognosis and response to therapy and in pulmonary arterial hypertension
Medrek, SK, Kloefkorn, C, Nguyen, DTM, Graviss, EA, Frost, AE & Safdar, Z 2017, Pulmonary Circulation, vol 7, no. 2, pp. 399-408. DOI: 10.1177/2045893217698715

Impact of declining renal function on outcomes in pulmonary arterial hypertension: A REVEAL registry analysis
Chakinala, MM, Coyne, DW, Benza, RL, Frost, AE, McGoon, MD, Hartline, BK, Frantz, RP, Selej, M, Zhao, C, Mink, DR & Farber, HW 2017, Journal of Heart and Lung Transplantation. DOI: 10.1016/j.healun.2017.10.028

Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial
Coghlan, JG, Galiè, N, Barberà, JA, Frost, AE, Ghofrani, H-A, Hoeper, MM, Kuwana, M, McLaughlin, VV, Peacock, AJ, Simonneau, G, Vachiéry, J-L, Blair, C, Gillies, H, Miller, KL, Harris, JHN, Langley, J, Rubin, LJ & AMBITION investigators 2016, Annals of the Rheumatic Diseases. DOI: 10.1136/annrheumdis-2016-210236

Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study
Hoeper, MM, McLaughlin, VV, Barberá, JA, Frost, AE, Ghofrani, HA, Peacock, AJ, Simonneau, G, Rosenkranz, S, Oudiz, RJ, White, RJ, Miller, KL, Langley, J, Harris, JHN, Blair, C, Rubin, LJ & Vachiery, JL 2016, The Lancet Respiratory Medicine, vol 4, no. 11, pp. 894-901. DOI: 10.1016/S2213-2600(16)30307-1

The Intersection of Pulmonary Hypertension and Solid Organ Transplantation
Frost, AE 2016, Houston Methodist DeBakey Cardiovascular Journal, vol 12, no. 4 Suppl, pp. 10-13. DOI: 10.14797/mdcj-12-4s1-10

Endothelin-1 pathway polymorphisms and outcomes in pulmonary arterial hypertension
Benza, RL, Gomberg-Maitland, M, Demarco, T, Frost, AE, Torbicki, A, Langleben, D, Pulido, T, Correa-Jaque, P, Passineau, MJ, Wiener, HW, Tamari, M, Hirota, T, Kubo, M & Tiwari, HK 2015, American Journal of Respiratory and Critical Care Medicine, vol 192, no. 11, pp. 1345-1354. DOI: 10.1164/rccm.201501-0196OC

Long-term safety and efficacy of imatinib in pulmonary arterial hypertension
Frost, AE, Barst, RJ, Hoeper, MM, Chang, HJ, Frantz, RP, Fukumoto, Y, Galié, N, Hassoun, PM, Klose, H, Matsubara, H, Morrell, NW, Peacock, AJ, Pfeifer, M, Simonneau, G, Tapson, VF, Torres, F, Dario Vizza, C, Lawrence, D, Yang, W, Felser, JM, Quinn, DA & Ghofrani, HA 2015, Journal of Heart and Lung Transplantation, vol 34, no. 11, pp. 1366-1375. DOI: 10.1016/j.healun.2015.05.025

Five-year outcomes of patients enrolled in the REVEAL registry
Farber, HW, Miller, DP, Poms, AD, Badesch, DB, Frost, AE, Muros-Le Rouzic, E, Romero, AJ, Benton, WW, Elliott, CG, McGoon, MD & Benza, RL 2015, Chest, vol 148, no. 4, pp. 1043-1054. DOI: 10.1378/chest.15-0300

Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension
Galie, N, Barbera, JA, Frost, AE, Ghofrani, HA, Hoeper, MM, McLaughlin, VV, Peacock, AJ, Simonneau, G, Vachiery, JL, Grunig, E, Oudiz, RJ, Vonk-Noordegraaf, A, White, RJ, Blair, C, Gillies, H, Miller, KL, Harris, JHN, Langley, J & Rubin, LJ 2015, New England Journal of Medicine, vol 373, no. 9, pp. 834-844. DOI: 10.1056/NEJMoa1413687

Validation of two predictive models for survival in pulmonary arterial hypertension
Sitbon, O, Benza, RL, Badesch, DB, Barst, RJ, Elliott, CG, Gressin, V, Lemarié, JC, Miller, DP, Rouzic, EML, Simonneau, G, Frost, AE, Farber, HW, Humbert, M & McGoon, MD 2015, European Respiratory Journal, vol 46, no. 1, pp. 152-164. DOI: 10.1183/09031936.00004414

Correction to Circulating Collagen Biomarkers as Indicators of Disease Severity in Pulmonary Arterial Hypertension [J Am Coll Cardiol HF, (2014), 2, 412-421]
Safdar, Z, Tamez, E, Chan, W, Arya, B, Ge, Y, Deswal, A, Bozkurt, B, Frost, A & Entman, M 2015, JACC: Heart Failure, vol 3, no. 4, pp. 345. DOI: 10.1016/j.jchf.2015.01.005

Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: A Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) analysis
Benza, RL, Miller, DP, Foreman, AJ, Frost, AE, Badesch, DB, Benton, WW & McGoon, MD 2015, Journal of Heart and Lung Transplantation, vol 34, no. 3, pp. 356-361. DOI: 10.1016/j.healun.2014.09.016

Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance
Farber, HW, Miller, DP, McGoon, MD, Frost, AE, Benton, WW & Benza, RL 2015, Journal of Heart and Lung Transplantation, vol 34, no. 3, pp. 362-368. DOI: 10.1016/j.healun.2014.08.020

Hospitalization and survival in patients using epoprostenol for injection in the PROSPECT observational study
Frantz, RP, Schilz, RJ, Chakinala, MM, Badesch, DB, Frost, AE, McLaughlin, VV, Barst, RJ, Rosenberg, DM, Miller, DP, Hartline, BK, Benton, WW & Farber, HW 2015, Chest, vol 147, no. 2, pp. 484-494. DOI: 10.1378/chest.14-1004

Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study
Chin, KM, Badesch, DB, Robbins, IM, Tapson, VF, Palevsky, HI, Kim, NH, Kawut, SM, Frost, A, Benton, WW, Lemarie, JC, Bodin, F, Rubin, LJ & McLaughlin, V 2014, American Heart Journal, vol 167, no. 2. DOI: 10.1016/j.ahj.2013.08.008

Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension
Simonneau, G, Rubin, LJ, Galiè, N, Barst, RJ, Fleming, TR, Frost, A, Engel, P, Kramer, MR, Serdarevic-Pehar, M, Layton, GR, Sitbon, O & Badesch, DB 2014, Journal of Heart and Lung Transplantation, vol 33, no. 7, pp. 689-697. DOI: 10.1016/j.healun.2014.02.019